Your search for Warfarin returned 10 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove

Your search for Warfarin returned 10 results

Sort Results:

Relevant Recent

FDA: Pradaxa vs. Warfarin Study Results Announced

The FDA announced the results of a new study on Medicare patients comparing Pradaxa (dabigatran etexilate mesylate; Boehringer Ingelheim Pharmaceuticals) vs. warfarin for risk of ischemic or clot-related stroke, bleeding in the brain, major gastrointestinal (GI) bleeding, myocardial infarction (MI), and death.

Benefits of Warfarin After Dementia Diagnosis Explored

For veterans receiving warfarin for nonvalvular atrial fibrillation, continuing warfarin after a diagnosis of dementia is associated with a protective effect in prevention of stroke and mortality, according to a study published online December 30 in the Journal of the American Geriatrics Society.

Drug Interaction Possible When HCV Regimens Added to Warfarin

A retrospective cohort study in the Annals of Pharmacotherapy found a clinically significant decrease in warfarin dose-response with concurrent hepatitis C treatments, especially with ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV-PTV/r-DSV).

Long-Term Warfarin in AFib Patients May Up Dementia Risk

Patients with atrial fibrillation taking long-term warfarin had higher rates of dementia than non-atrial fibrillation patients, a study presented at the Heart Rhythm Society's 37th Annual Scientific Sessions has found.

Kcentra Approved for Urgent Reversal of Warfarin in Emergency Surgery Setting

The FDA has approved the expanded indication for Kcentra (Prothrombin Complex Concentrate [Human]; CSL Behring) to include the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients needing an urgent surgery or other invasive procedure.

FDA Approves Eliquis for Nonvalvular AFib

Bristol-Myers Squibb and Pfizer announced that the FDA has approved Eliquis (apixaban tablets) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

GI Bleed Hospitalization Risk Linked to Oral Anticoagulant Choice, PPI Cotherapy

To compare the incidence of hospitalization for upper GI tract bleeding, researchers used US Medicare beneficiary files to identify a cohort of patients that were ≥30 years old who initiated oral anticoagulation therapy with apixaban, dabigatran, rivaroxaban, or warfarin, with or without PPI cotherapy.